Check out Total Prescribing Details OPDIVO® (nivolumab) is indicated with the treatment of adult patients with classical Hodgkin lymphoma (cHL) which has relapsed or progressed soon after autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or soon after 3 or more strains of systemic therapy that includes autologous